Somatostatin and cancer

Metabolism: Clinical and Experimental

Volumn 45, Issue SUPPL.1, 1996, Pages 98-100

  Robbins, R J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIM 32014; OCTREOTIDE; OCTREOTIDE[3 TYROSINE]; PENTETREOTIDE IN 111; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ASTROCYTOMA; BREAST CANCER; COLON CANCER; DIGESTIVE SYSTEM CANCER; DRUG ACTIVITY; GLIOMA; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MELANOMA; MENINGIOMA; NEUROBLASTOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; THYROID CANCER;

CELL DIVISION; ENDOCRINE GLAND NEOPLASMS; HUMANS; NERVOUS SYSTEM NEOPLASMS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0029814431     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(96)90096-7     Document Type: Article

References (41)

1. Brazeau P, Vale W, Burgus R, Ling M, et al: Hypothalamic peptide that inhibits the secretion of immunoreactive growth hormone. Science 179:77-79, 1973
2. Weiss R, Reddi A, Nimni M: Somatostatin can locally inhibit proliferation and differentiation of cartilage and bone precursor cells. Calcif Tissue Int 33:425-430, 1981
3. Mascardo R, Sheline P: Somatostatin inhibits rapid centrosomal separation and cell proliferation induced by epidermal growth factor. Endocrinology 111:1394-1396, 1982
4. Taylor J: Somatostatin (SSTR2) receptors mediate phospholipase C independent calcium mobilization in rat AR42J pancreas cells. Biochem Biophys Res Commun 214:81-85, 1995
5. Sussman K, Leitner J, Rifkin R: Somatostatin: Selective inhibition of cyclic AMP stimulated protein kinase. Trans Assoc Am Physicians 91:129-134, 1978
6. Catalan R, Miguel B, Godoy J, et al: Regulation of phosphoprotein phosphatase by somatostatin. Biochem Med 31:36-41, 1984
7. Reisine T, Bell G: Molecular biology of somatostatin receptors. Endocr Rev 16:427-442, 1995
8. Zhang C, Yokogoshi Y, Yoshimoto K, et al: Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line, COR-L103. Biochem Biophys Res Commun 210:805-815, 1995
9. Reubi J, Laissue J: Multiple actions of somatostatin in neoplastic disease. Trends Pharmacol Sci 16:110-115, 1995
10. Hofland L, van der Berg B, van Eijck C, et al: Role of tumor-derived fibroblasts in the growth of primary cultures of human breast-cancer cells: Effects of EGF and the somatostatin analog octreotide. Int J Cancer 60:93-99, 1995
11. Patel P, Barrie R, Hill N, et al: Postreceptor signal transduction mechanisms involved in octreotide-induced inhibition of angiogenesis. Surgery 116:1148-1152, 1994
12. Reubi J, Horisberger U, Laissue J: High density of somatostatin receptors in veins surrounding human cancer. Int J Cancer 56:681-688, 1994
13. Reubi J, Kvols L: Somatostatin receptors in human renal cell carinomas. Cancer Res 52:6074-6078, 1992
14. Van Eijck C, Krenning E, Bootsma A, et al: Somatostatin-receptor scintigraphy in primary breast cancer. Lancet 343:640-643, 1994
15. Leitha T, Meghdadi S, Studnicka M, et al: The role of iodine-123-tyr-3 octreotide scintigraphy in the staging of small-cell lung cancer. J Nucl Med 34:1397-1403, 1993
16. IIIIn]pentetreotide, a radiolabelled somatostatin analogue. Br J Cancer 69:762-766, 1994
17. Kwekkeboom D, Kho G, Lamberts S, et al: The value of octreotide scintigraphy in patients with lung cancer. Eur J Nucl Med 21:1106-1113, 1994
18. Kirsch C, von Pawel J, Grau I, et al: Indium-111 pentetreotide in the diagnostic work-up of patients with bronchogenic carcinoma. Eur J Nucl Med 21:1318-1325, 1994
19. Scheidhauer K, Hildebrand G, Luyken C, et al: Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: First experiences. Horm Metab Res 27:59-64, 1993 (suppl)
20. Haldemann A, Rosier H, Barth A, et al: Somatostatin receptor scintigraphy in central nervous system tumors: Role of blood-brain barrier permeability. J Nucl Med 36:403-410, 1995
21. Reubi J, Waser B, van Hagen M, et al: In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas. Int J Cancer 50:895-900, 1992
22. Tenenbaum F, Lumbroso J, Schlumberger M, et al: Radiolabeled somatostatin analog scintigraphy in differentiated thyroid cancer. J Nucl Med 36:807-810, 1995
23. Bong S, Vander J, Laan H, et al: Clinical experience with somatostatin receptor imaging in lymphoma. Semin Oncol 21:46-51, 1994 (suppl 13)
24. Bares R, Galonska P, Dempke W, et al: Somatostatin receptor scintigraphy in malignant lymphoma: First results and comparison with glucose metabolism measured by positron-emission tomography. Horm Metab Res 27:56-59, 1993 (suppl)
25. Sautter-Bihl M, Dorr U, Schilling F, et al: Somatostatin receptor imaging: a new horizon in the diagnostic management of neuroblastoma. Semin Oncol 21:38-43, 1995 (suppl 13)
26. Lamberts S, Bakker W, Reubi J, et al: Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med 323:1246-1249, 1990
27. Kwekkeboom D, van Urk H, Pauw K, et al: Octreotide scintigraphy for the detection of paraganglioma. J Nucl Med 34:873-877, 1993
28. Hoefnagel C, Rankin E, Validesolmos R, et al: Sensitivity versus specificity in melanoma imaging using iodine-123 iodobenzamide and indium-111 pentetreotide. Eur J Nucl Med 21:587-593, 1994
29. 111Indium (DTPA octreotide) scintigraphy in patients with cerebral gliomas. Acta Neurochir (Wein) 127:60-65, 1994
30. Koper J, Reubi J, Krenning E: Endocrine aspects of diagnosis and treatment of primary brain tumors. Clin Endocrinol 35:1-35, 1992
31. Parmar H, Charlton A, Phillips R, et al: Therapeutic response to somatostatin analogue BIM 23014 in metastatic prostatic cancer. Clin Exp Metastasis 10:3-11, 1992
32. Maulard C, Richaud P, Droz J, et al: Phase I-II study of the somatostatin analogue lanreotide in hormone-refractory prostate cancer. Cancer Chemother Pharmacol 36:259-262, 1995
33. Goldberg R, Moertel C, Wieand H, et al: A phase III evaluation of a somatostatin analogue (octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer 76:961-966, 1995
34. Stewart G, Connor J, Lawson J, et al: Octreotide reduces the kinetic index, proliferating cell nuclear antigen-maximum proliferative index, in patients with colorectal cancer. Cancer 776:572-578, 1995
35. Vennin P, Peyrat J, Bonneterre J, et al: An effect of the long-acting somatostatin analog SMS201-995 (Sandostatin) in advanced breast cancer. Anticancer Res 9:153-156, 1989
36. Stolfi R, Parisi A, Natoli C, et al: Advanced breast cancer: Response to somatostatin. Anticancer Res 10:203-204, 1990
37. Manni A, Boucher A, Demers L, et al: Endocrine effects of combined somatostatin analog and bromocriptine therapy in women with advanced breast cancer. Breast Cancer Res Treat 14:289-294, 1989
38. Klijn J, Hoff A, Planting A, et al: Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: A phase II study including endocrine effects. Br J Cancer 62:627-630, 1990
39. Macaulay V, Smith I, Everard M, et al: Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. Br J Cancer 64:451-456, 1995
40. Diaco D, Hajarizadeh H, Mueller C, et al: Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide, intra-arterial chemotherapy, and hepatic artery embolization. Am J Surg 169:523-528, 1995
41. Weckbecker G, Tolcsvai L, Stolz B, et al: Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on DMBA-induced mammary carcinomas. Cancer Res 54:6334-6337, 1994